Skip to content
thestock.space

Akums Drugs and Pharmaceuticals (AKUMS) had a P/E of 30.9× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 12% below their 52-week high. Sales and net profit grew 7.0% and 39% a year over 3 years; its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹11,252 Cr, ranked 32nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 58% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹735.00
Day high
₹749.45
Day low
₹732.00
Prev. close
₹744.60
Volume
1.3 L

Health check

3 good · 2 fair · 1 to check
  • ReturnsAhead

    +58.1% over a year, better than 6 of 7 peers.

  • Price tagIn line

    P/E 30.9 vs industry 28.7.

  • GrowthSteady

    Sales +7.0%, profit +39.1% a year over 3 years.

  • ProfitabilityWeak

    ROCE 10.8% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 6 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹11,252 Cr, #32 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹4,829 Cr · profit ₹364 Cr
Market cap
₹11,252 Cr
Small cap
P/E
30.9
Industry 28.7
Price to book
3.21
Peers 4.99
Dividend yield
0.14%
ROE
10.9%
Peers 14.7%
ROCE
10.8%
Peers 17.9%
Debt to equity
0.03
Debt ₹117 Cr
EPS (TTM)
₹23.76
Face value ₹2
OPM (TTM)
13.8%
Net margin 7.5%
Sales growth
+31.9%
Latest quarter vs a year ago
Profit growth
+176.7%
Latest quarter vs a year ago
Price to sales
2.33
EV/EBITDA 14.8

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 176.7% on a year ago.
  • Quarterly sales up 31.9% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including…

Headquarters
Delhi
Employees
7,337
Sector
Healthcare
ISIN
INE09XN01023
Website
akums.in

Price range

52 weeks

₹409.30₹838.80

Today

₹732.00₹749.45
Avg volume (3M)
3.5 L
1-year return
plus 58.1%
From 52-week high
minus 12.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
AKUMSAkums Drugs and Pharmaceuticals734.95minus 1.30%11,25230.93.2110.8%10.9%13.8%7.0%39.1%0.14%plus 58.1%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
1,0181,1601,1581,1671,342
9231,0131,0069921,148
94.5147152175195
9.3%12.7%13.1%15.0%14.5%
2934.335.330.423.4
19.923.723.924.820.2
37.939.640.141.143.2
–−18.2−1.8––
65.799.6121139155
35.0%32.0%32.9%27.5%26.0%
40.866.384.6100113
2.664.335.536.537.37

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+7.0%
Profit CAGR 3Y
+39.1%
EPS CAGR 3Y
+40.4%
ROE
10.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,4754,0204,0714,251
–+15.7%+1.3%+4.4%
3,1713,8893,6073,723
304131464529
8.8%3.2%11.4%12.4%
31.138641117
4650.330.488.6
113126153155
−26.2−38624−20.1
150−45.3345382
34.9%101.7%0.4%32.9%
94.9−4338255
–minus 104.3%–minus 24.5%
6.03-0.2822.6016.67

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
28.628.630.630.6
6896813,0163,283
61956588.2192
1,9302,2429781,942
3,2673,5164,1135,447
1,2121,3911,5641,650
123209173201
0.20.30.30.2
1512885821,681
1,7811,6291,7941,915
3,2673,5164,1135,447

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1774984651,181
−305−330−548−930
125−10872.833.9
−3.559.8−9.9285
−329−311−272−231
−152187193951

Shareholding pattern

Source: NSE filings
75.3%
promoters
  • Promoters75.26%
  • Public22.01%
  • Employee trusts2.73%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202675.26%22.01%0.00
30 Jun 202675.26%22.01%0.00
31 Mar 202675.26%22.01%0.00
31 Dec 202575.26%22.01%0.00
30 Sep 202575.26%22.01%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you